1. Bristol-Myers Pushes Celgene Deal, Starboard Hits Back, in $74B Takeover Spat

    Bristol-Myers Pushes Celgene Deal, Starboard Hits Back, in $74B Takeover Spat

    Bristol-Myers Squibb ( BMY ) traded blows with activist investor Starboard Value LP Tuesday as the pair issued competing presentations linked to the pharmaceutical group's planned $74 billion takeover of cancer drug specialist Celgene Corp. ( CELG )...

    Read Full Article

    Login to comment.

  1. Categories

    1. BoardProspects Features:

      BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, In the News, Partner Publications, Sponsored Content
  2. Quotes

    1. We believe there is a better path forward for Bristol-Myers, either as a more profitable standalone company with a more focused, lower-risk strategy, or in a potential sale of the whole Company.
    2. Since announcing the Celgene transaction on January 3, our Board and management team have had numerous conversations and meetings with our stockholders across our ownership base, including Wellington.
  3. Topics Mentioned

  4. Authors